Sonnet BioTherapeutics to Present at Prominent Cancer Research Conference
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a pioneering clinical-stage biotechnology firm focused on developing innovative immunotherapeutic drugs, has exciting news to share. The company has had its abstract accepted for poster presentation at one of the most significant conferences in the oncology field, the 2025 American Association for Cancer Research (AACR) IO Conference. This event is scheduled from February 23-26, 2025, and will take place at the JW Marriott in Los Angeles.
Details of the Presentation
Attendees can look forward to a detailed exploration of Sonnet's research during Poster Session B. The abstract is titled “Combination immunotherapy with an albumin-binding interleukin-12 fusion protein that extends cytokine half-life, targets the tumor microenvironment, and enhances therapeutic efficacy.” This important presentation will be held on Tuesday, February 25, 2025, from 1:45-4:45 PM PT.
What is Sonnet BioTherapeutics?
Sonnet BioTherapeutics is known for its unique approach to fighting cancer through targeted biologic therapies. Their proprietary FHAB (Fully Human Albumin-Binding) technology allows them to develop drugs that specifically target tumors and lymphatic tissue while utilizing the body's own transport mechanisms. This targeted approach enhances the safety and efficacy of biologic drugs designed to modulate immune responses.
Innovative Drug Development
Central to their development pipeline is SON-1010, or IL-12-FHAB, which is being tested as a treatment for various advanced solid tumors, including specific sarcomas and platinum-resistant ovarian cancer (PROC). This program is currently in an ongoing Phase 1/2a clinical study, leveraging a collaboration with Roche. The study is notable for combining SON-1010 with atezolizumab, a well-known immune checkpoint inhibitor. The early data from these studies are highly promising and support the potential broadened application of immunotherapies.
Expanding Horizons with New Candidates
In addition to SON-1010, Sonnet is actively engaged in the development of SON-1210, another candidate designed for treating solid tumors. This candidate combines IL-12-FHAB with IL-15 and is being explored through a partnership with the Innovative Immuno-Oncology Consortium (IIOC). There are plans for an investigator-initiated and funded Phase 1/2a study targeting locally-advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
Sonnet’s Commitment to Neuropathy Research
Moreover, the company is advancing their SON-080 program, which focuses on the treatment of Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN). Encouraging results have emerged from the Phase 1b/2a clinical trial where SON-080 was well-tolerated, showing no signs of pro-inflammatory cytokine response. Recently, Sonnet entered into a licensing agreement with Alkem Laboratories, Inc., which will lead the development of SON-080 into a continuation into a Phase 2 study in DPN.
Why Attend the AACR Conference?
The AACR Climate Conference represents a wonderful opportunity for Sonnet to share its latest findings with a community of researchers and healthcare professionals dedicated to cancer research and treatment. By presenting at such a prestigious conference, the company also seeks to attract attention to its innovative therapies, gather insights from peers, and forge potential collaborations aimed at advancing cancer treatments.
Future Directions
As Sonnet BioTherapeutics continues to develop its innovative therapies, the company remains committed to enhancing the quality of life for cancer patients and addressing unmet medical needs. Their ongoing clinical trials and collaborations reflect an eagerness to advance the scientific understanding and therapeutic landscape in oncology.
Frequently Asked Questions
What is the significance of Sonnet's presentation at the AACR conference?
This presentation highlights Sonnet's contributions to cancer immunotherapy and allows for networking with other professionals in the field.
What technologies does Sonnet BioTherapeutics use?
Sonnet uses its FHAB technology to develop targeted biologic therapies specifically aimed at tumor and lymphatic tissues.
What are SON-1010 and SON-1210?
SON-1010 and SON-1210 are advanced immunotherapeutics currently in development for treating solid tumors and enhancing the efficacy of cancer treatments.
How is Sonnet involved in neuropathy treatment?
Sonnet's SON-080 program is designed to address chemotherapy-induced and diabetic peripheral neuropathy with promising clinical results.
Where can I learn more about Sonnet BioTherapeutics?
For further information, you can contact their investor relations team or visit their official website.
